跳至主要内容
临床试验/NCT05926063
NCT05926063招募中4 期

Stopping Antibiotics After 3 Days for the Treatment of FEbrile Neutropenia in Haematology Patients (SAFE Study): a Randomized Open-label Non-inferiority Trial

Universitaire Ziekenhuizen KU Leuven2 个研究点 分布在 1 个国家目标入组 410 人开始时间: 2024年2月26日最近更新:
适应症

试验速览

阶段
4 期
状态
招募中
入组人数
410
试验地点
2
主要终点
Absence of a serious medical complication (SMC) following 42 days after randomisation. SMC is defined as: Death; and/or ICU admission; and/or Septic shock requiring vasopressive therapy.

研究概览

简要总结

The goal of this clinical trial is to compare a short course of antibiotics in patients in whom no bacterial infection is found with the current "golden standard": long-term antibiotic treatment in adult hematology patients who develop neutropenic fever.

The main question it aims to answer is: whether the short-term treatment is equally safe for patients, hence the name 'SAFE study'.

Participants will be randomly assigned (randomized) to one of two treatment options once they develop neutropenic fever: short-term or long-term antibiotic treatment. An additional blood sample, urine sample and stool sample will be collected.

Researchers will compare the short-term and the long-term antibiotic treatment groups to see if the short treatment is equally safe as the long-term treatment group.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
None

入排标准

年龄范围
16 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures;
  • Age older than 16 years;
  • Intensive therapy is started within three days before randomization for one of the following haematological conditions:
  • Remission induction chemotherapy for newly diagnosed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); OR
  • Re-induction chemotherapy for relapsed after haematological remission lasting for a minimum duration of 6 months; OR
  • Conditioning regimen to prepare for an allogeneic HCT; OR
  • Conditioning regimen to prepare for an autologous HCT.
  • Expected longstanding (≥ 7 days) neutropenia (ANC < 0.5x10^9/L);
  • Expected length of hospital stay of at least 10 days.

排除标准

  • Clinically or microbiologically documented infection;
  • Patient already receives broad spectrum antibiotic therapy;
  • Any critical illness for which Intensive Care Unit treatment is required;
  • SOFA score ≥ 11;
  • Longstanding neutropenia (>21 days) prior inclusion;
  • Previous enrolment in this study;
  • Not able to provide written informed consent;
  • Any disorder, which in the Investigator's opinion might jeopardise the participant's safety or compliance with the protocol;
  • Any prior or concomitant treatment(s) that might jeopardise the participant's safety or that would compromise the integrity of the Trial.

结局指标

主要结局

Absence of a serious medical complication (SMC) following 42 days after randomisation. SMC is defined as: Death; and/or ICU admission; and/or Septic shock requiring vasopressive therapy.

时间窗: 42 days

次要结局

  • Number of readmissions within 42 days(42 days)
  • Incidence of candidemia(42 days)
  • Length of hospital stay in the first 42 days after randomization(42 days)
  • Number of patients admitted to the ICU within 42 days after randomisation(42 days)
  • Number of patients with a culture (surveillance or diagnostic culture) positive for resistant bacteria: VRE; ESBL; MRSA; and/or CPE(42 days)
  • Clinically documented infections(42 days)
  • Total days of non-prophylactic antibiotics given to the patient at engraftment(42 days)
  • Incidence, severity and duration of diarrhea(42 days)
  • Number of patients in the short treatment arm with ongoing fever at time of EBAT stop(42 days)
  • Incidence of bacteraemia within 42 days after randomisation(42 days)
  • Total numbers of antibiotic switches before neutrophil recovery(42 days)
  • Incidence of Clostridium difficile infection(42 days)
  • Duration of hospitalization(42 days)
  • Number of documented bacterial infections(42 days)
  • Incidence of acute GVHD (grade II or higher) in the transplanted study population(42 days)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验